XOMA Royalty Corporation announced the completion of its acquisition of HilleVax, Inc. On September 16, 2025, XOMA and its wholly owned subsidiary, XRA 4 Corp., successfully concluded a tender offer to purchase all outstanding shares of HilleVax's common stock. Shareholders received $1.95 per share in cash, along with a non-transferable contractual contingent value right. The transaction was finalized without requiring a vote from HilleVax stockholders. The merger was officially completed on September 17, 2025, with XRA 4 Corp. merging into HilleVax, as announced in XOMA's recent press release.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-213583), on September 23, 2025, and is solely responsible for the information contained therein.